Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment
Journal of Medicinal Chemistry · 26.06.2025 · 68 (12) · 12593-12614
DOI: 10.1021/acs.jmedchem.5c00344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.06.2025. Verfasst von Zichao Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutic…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Resorcinols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Current studies on PD-1/PD-L1 small-molecule inhibitors mainly focus on modifying the linker region between the biphenyl ring and amino acid side chains, or transforming the biphenyl ring into a benzodioxane structure. Herein, we designed and synthesized a series of compounds by introducing a tail at the terminal phenyl ring as small-molecule PD-1/PD-L1 inhibitors. Among them, compound NPH16 exhibited the most potent PD-L1 inhibitory activity (IC50 = 24.4 nM). The X-ray crystal structure further confirmed the high binding affinity of NPH16 to PD-L1 dimer. In the HepG2/Jurkat T cell coculture model, NPH16 promoted HepG2 cell apoptosis dose-dependently. In addition, NPH16 showed excellent in vivo antitumor efficacy (TGI = 92.1%) in a Hepa1-6 mouse tumor model and increased CD8+ cells in tumor microenvironment. Importantly, NPH16 possessed favorable pharmacokinetic properties with an oral bioavailability of 15.9%. Collectively, compound NPH16 represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a potential anticancer agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- State Key Laboratory of Natural Medicines and Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China.
- The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, China.
ORCID-Profile: Jianjun Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, Z., Yang, P., Xu, J., Yang, X., Zhou, J., He, H., Li, L., Ren, Y., Chen, M., Xiao, Y., & Chen, J. (2025). Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. Journal of Medicinal Chemistry, 68(12), 12593-12614. https://doi.org/10.1021/acs.jmedchem.5c00344
Vancouver
Yang Z, Yang P, Xu J, Yang X, Zhou J, He H, et al. Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. Journal of Medicinal Chemistry. 2025;68(12):12593-12614. doi:10.1021/acs.jmedchem.5c00344
BibTeX
@article{Yang2025,
author = {Yang, Zichao and Yang, Pan and Xu, Jianwei and Yang, Xixiang and Zhou, Jiayi and He, Haiqi and Li, Ling and Ren, Yichang and Chen, Meirong and Xiao, Yibei and Chen, Jianjun},
title = {Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {12},
pages = {12593--12614},
doi = {10.1021/acs.jmedchem.5c00344}
}
EUVIMED